Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 5, 2014, Pages

  Lecavalier Barsoum, Magali ^a   Quon, Harvey ^b   Abdulkarim, Bassam ^c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b CANCERCARE MANITOBA   (Canada)

^c MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; TEMOZOLOMIDE; TUMOR MARKER; VINCRISTINE;

ASTROCYTOMA; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; GENE MUTATION; HUMAN; OLIGODENDROGLIOMA; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ADULT; BRAIN NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; ASTROCYTOMA; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; HUMANS; OLIGODENDROGLIOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84937590219     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007104.pub2     Document Type: Review

References (39)

1. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, et al.Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. Journal of Clinical Oncology 2006;24(18):2707-14.
2. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al.Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. Journal of Clinical Oncology 2013;31:337-43.
3. Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, et al.Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. Journal of Clinical Oncology 2014;32(8):783-90.
4. Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M, et al.Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathology 2008;18:360-9.
5. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, et al.NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of Clinical Oncology 2009;27(35):5874-80.
6. Idbaih A, Dalmasso C, Kouwenhoven M, Jeuken J, Carpentier C, Gorlia T, et al.Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. Journal of Neuro-oncology 2011;103:221-30.
7. Kouwenhoven MC, Gorlia T, Kros JM, Ibdaih A, Brandes AA, Bromberg JE, et al.Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro-oncology 2009;11:737-46.
8. Mauer ME, Taphoorn MJ, Bottomley A, Coens C, Efficace F, Sanson M, et al.Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. Journal of Clinical Oncology 2007;25:5731-37.
9. Mokhtari K, Ducray F, Kros JM, Gorlia T, Idbaih A, Taphoorn M, et al.Alpha internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy. Cancer 2011;117:3014-26.
10. van den Ben MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, et al.Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology 2013;31:344-50.
11. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, et al.Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of Clinical Oncology 2006;24(18):2715-22.
12. van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, et al.IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Research 2010;16:1597-604.
13. van den Bent MJ, Dubbink HJ, Sanson M, van der Lee-Haarloo CR, Hegi M, Jeuken JW, et al.MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology 2009;27:5881-6.
14. van den Bent MJ, Gravendeel LA, Gorlia T, Kros JM, Lapre L, Wesseling P, et al.A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clinical Cancer Research 2011;17:7148-55.
15. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathologica 2008;116(6):597-602.
16. Boots-Sprenger SH, Sijben A, Rijntjes J, Tops BB, Idema AJ, Rivera AL, et al.Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution. Modern Pathology 2013;26(7):922-9.
17. Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, et al.Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 1994;12(10):2013-21.
18. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al.Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. Journal of the National Cancer Institute 1998;90(19):1473-9.
19. Camelo-Piragua S, Jansen M, Ganguly A, Kim JC, Louis DN, Nutt CL. Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. Acta Neuropathologica 2010;119:509-11.
20. Central Brain Tumor Registry of the United States. Primary brain tumors in the United States statistical report, 2005-2009. Neuro-oncology 2009; Vol. 14 Suppl 5:v1-49.
21. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, et al.Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1, 010 diffuse gliomas. Acta Neuropathologica 2009;118:469-74.
22. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al.The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
23. Ichimura K, Pearson DM, Kocialkowski S, Bäcklund LM, Chan R, Jones DT, et al.IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-oncology 2009;11:341-7.
24. Kloosterhof NK, Bralten LB, Dubbink HJ, French PJ, van den Bent MJ. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?. The lancet oncology 2011;12:83-91.
25. Kouwenhoven MC, Gorlia T, Kros JM, Ibdaih A, Brandes AA, Bromberg JE, et al.Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro-oncology 2009;11:737-46.
26. Laffaire J, Everhard S, Idbaih A, Crinière E, Marie Y, de Reyniès A, et al.Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro-oncology 2011;13:84-98.
27. Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, et al.International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro-oncology 2011;13:649-59.
28. Li S, Yan C, Huang L, Qiu X, Wang Z, Jiang T. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China. Neuro-oncology 2012;14:109-16.
29. NCT00626990. Radiation therapy with or without temozolomide in treating patients with anaplastic glioma. clinicaltrials.gov/ct2/show/NCT00626990 (accessed 13 May 2014).
30. NCT00887146. Radiation therapy with concomitant and adjuvant temozolomide or radiation therapy with adjuvant PCV or temozolomide alone in treating patients with anaplastic glioma. clinicaltrials.gov/show/NCT00887146 (accessed 13 May 2014).
31. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
32. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al.An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12.
33. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, et al.Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. Journal of Clinical Oncology 2000;18(3):636-45.
34. Sonoda Y, Kumabe T, Nakamura T, Kanamori M, Yamashita Y, Suzuki H, et al.Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Science 2009;100:1996-8.
35. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al.Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine 2005;352:987-96.
36. van den Bent MJ, Looijenga LH, Langenberg K, Dinjens W, Graveland W, Uytdewilligen L, et al.Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 2003;97:1276-84.
37. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. American Journal of Pathology 2009;174:1149-53.
38. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al.IDH1 and IDH2 mutations in gliomas. New England Journal of Medicine 2009;360:765-73.
39. Quon H, Abdulkarim B. Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD007104].